We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer.